Results 21 to 30 of about 6,247,192 (199)

Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background The United Kingdom relapsed Wilms tumour (UKW‐R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk‐stratified protocol. The trial also evaluated efficacy and toxicity of high‐dose melphalan.
Sucheta J. Vaidya   +10 more
wiley   +1 more source

$$d_{N \Omega }$$ d N Ω production in $$\Omega d$$ Ω d scattering process

open access: yesEuropean Physical Journal C: Particles and Fields
In the present work, we propose to investigate the production of $$d_{N \Omega }$$ d N Ω in the $$\Omega ^{-} d \rightarrow p d_{N \Omega }^-$$ Ω - d → p d N Ω - process by utilizing an effective Lagrangian approach, where $$d_{N \Omega }$$ d N Ω is ...
Quan-Yun Guo, Jing Liu, Dian-Yong Chen
doaj   +1 more source

N $$ \mathcal{N} $$ -extended D = 4 supergravity, unconventional SUSY and graphene

open access: yesJournal of High Energy Physics, 2020
We derive a 2+1 dimensional model with unconventional supersymmetry at the boundary of an AdS4 N $$ \mathcal{N} $$ -extended supergravity, generalizing previous results. The (unconventional) extended supersymmetry of the boundary model is instrumental in
L. Andrianopoli   +6 more
doaj   +1 more source

The head of the nominal is N, not D: N-to-D Movement, Hybrid Agreement, and conventionalized expressions

open access: yesGlossa, 2020
The DP Hypothesis has recently come under intense criticism (Bruening 2009, Bruening et al. 2018). In the face of this criticism, several responses have been offered. This paper addresses three such responses and shows that they are without force. First,
Benjamin Bruening
doaj   +2 more sources

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman   +17 more
wiley   +1 more source

Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens.
Matthew T. McEvoy   +5 more
wiley   +1 more source

Wilson loops in N $$ \mathcal{N} $$ = 4 SO(N) SYM and D-branes in AdS5 × ℝℙ5

open access: yesJournal of High Energy Physics, 2021
We study the half-BPS circular Wilson loop in N $$ \mathcal{N} $$ = 4 super Yang-Mills with orthogonal gauge group. By supersymmetric localization, its expectation value can be computed exactly from a matrix integral over the Lie algebra of SO(N).
Simone Giombi, Bendeguz Offertaler
doaj   +1 more source

Criterion‐Related Validity of the Neuropsychological Quick Assessment for Screening Cognitive, Motor, and Behavioral Impairments in Patients With Pediatric Brain Tumors: An Observational Pilot Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Neuropsychological complications may impair the qualitative prognosis of patients with pediatric brain tumors. However, multifaceted evaluations cannot be conducted in all patients because they are time consuming and burdensome for patients.
Ami Tabata   +9 more
wiley   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson   +20 more
wiley   +1 more source

HUDOKORMOV D. N.

open access: yesЛитьë и металлургия, 2009
. (to the 85-th anniversary)
article editotial
doaj  

Home - About - Disclaimer - Privacy